Related references
Note: Only part of the references are listed.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy
Zuqiang Liu et al.
ONCOIMMUNOLOGY (2016)
Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells
Ann Ager et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer
Lily Francis et al.
ONCOTARGET (2016)
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
CAR therapy: the CD19 paradigm
Michel Sadelain
JOURNAL OF CLINICAL INVESTIGATION (2015)
Replicating poxviruses for human cancer therapy
Manbok Kim
JOURNAL OF MICROBIOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
Tengfei Zhang et al.
ONCOTARGET (2015)
Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors
Nobuhiro Nishio et al.
ONCOIMMUNOLOGY (2015)
Technical Advance: An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells
Jon G. Quatromoni et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2015)
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors
Nobuhiro Nishio et al.
CANCER RESEARCH (2014)
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
Markus Chmielewski et al.
IMMUNOLOGICAL REVIEWS (2014)
CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors
Matteo Santoni et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Immunotherapeutic potential of oncolytic vaccinia virus
Steve H. Thorne
FRONTIERS IN ONCOLOGY (2014)
Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
Matthew J. Riese et al.
CANCER RESEARCH (2013)
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus
Anna Kanerva et al.
CLINICAL CANCER RESEARCH (2013)
Crosstalk Between Immune Cell and Oncolytic Vaccinia Therapy Enhances Tumor Trafficking and Antitumor Effects
Padma Sampath et al.
MOLECULAR THERAPY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Local Delivery of Interleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
Dhanalakshmi Chinnasamy et al.
CLINICAL CANCER RESEARCH (2012)
Treating Tumors With a Vaccinia Virus Expressing IFNβ Illustrates the Complex Relationships Between Oncolytic Ability and Immunogenicity
Liang-Chuan S. Wang et al.
MOLECULAR THERAPY (2012)
Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity
Jun Li et al.
NEOPLASIA (2012)
Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
Michelle Hong et al.
CANCER RESEARCH (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy
Jeong Heo et al.
MOLECULAR THERAPY (2011)
Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer
Jun Li et al.
MOLECULAR THERAPY (2011)
Regulation of T Cell Activation and Anergy by the Intensity of the Ca2+ Signal in Cooperation with Other Signals
Yu Adachi et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin et al.
CANCER RESEARCH (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Immunotherapy of murine hepatocellular carcinoma by α-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression
Maria Matilde Bartolome Rodriguez et al.
HUMAN GENE THERAPY (2008)
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma
Ta-Chiang Liu et al.
MOLECULAR THERAPY (2008)
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus
David H. Kirn et al.
PLOS MEDICINE (2007)
Adoptive T cell therapy for cancer in the clinic
Carl H. June
JOURNAL OF CLINICAL INVESTIGATION (2007)
Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture
Klara Berencsi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine
AR Haas et al.
CLINICAL CANCER RESEARCH (2006)
The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis
PJ Hensbergen et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins
V Heissmeyer et al.
NATURE IMMUNOLOGY (2004)
Synergistic effect of adoptive T-cell therapy and intratumoral interferon γ-inducible protein-10 transgene expression in treatment of established tumors
H Huang et al.
CELLULAR IMMUNOLOGY (2002)
Share Paper
